New antibiotics against Gram-positive microorganisms: Linezolid, tigecycline, daptomycin, dalbavancin, telavancin, ceftobiprole;Nuevos antibióticos frente a grampositivos: Linezolid, tigeciclina, daptomicina, dalbavancina, telavancina, ceftobiprole

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 2, 2008, Pages 13-20

  Soriano, Francisco ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Ceftobiprole; Dalbavancin; Daptomycin; Linezolid; Telavancin; Tigecycline

Indexed keywords

CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; DALBAVANCIN; DAPTOMYCIN; LINEZOLID; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG MECHANISM; GRAM POSITIVE BACTERIUM; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; RECOMMENDED DRUG DOSE; REVIEW; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 46049109185     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13126267     Document Type: Article

References (65)

1. Ford CW, Zurenko GE, Barbachyn MR. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr Drug Tragets Infect Disord. 2001;1:181-99.
2. Pigrau C. Oxazolidinonas y glucopéptidos. Enferm Infecc Microbiol Clin. 2003;21:157-65.
3. Jones RN, Stilwell MG, Hogan PA, Sheehan DJ. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2007;51:1491-3.
4. Jones RN, Ross JE, Fritsche TR, Sader HS. Oxazolidinone susceptibility patterns in 2004: report from the ZyvoxR annual appraisal of potency and spectrum (ZAAPS) program assessing isolates from 16 nations. J Antimicrob Chemother. 2006;57:279-87.
5. Chin JN, Rybak MJ, Cheung CM, Savage PB. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:1268-73.
6. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and resistant strains. Antimicrob Agents Chemother. 2000;44:1062-6.
7. Wallace RJ Jr, Brown-Elliott BA, Ward SC, Crist CJ, Mann LB, Wilson RW. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2001;45:764-7.
8. Alcalá L, Ruiz-Serrano MJ, Pérez Fernández Turegano C, García de Viedma D, Díaz-Infantes M, Marin-Arriaza M, et al. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother. 2003;47:416-7.
9. Goldstein EJ, Citron DM, Merriam CV. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans. Antimicrob Agents Chemother. 1999;43:1469-74.
10. Meka VG, Gold HS. Antimicrobial resistance to linezolid. Clin Infect Dis. 2004;39:1010-5.
11. MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections. J Antimicrob Chemother. 2003;51 Suppl 2:17-25.
12. EUCAST technical note on linezolid. Clin Microbiol Infect. 2006;12:1243-5.
13. Andes D, van Ogtrop ML, Peng J, Craig WA. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002;46:3484-9.
14. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; seventeen informational supplement. Wayne: CLSI document M100-S17; 2007.
15. Noskin GA. Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 2005;41 Suppl 5:303-14.
16. Bergeron J, Ammirati M, Danley D, James L, Norcia M, Retsema J, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother. 1996;40:2226-8.
17. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ. In vitro activity of tigecycline against 6792 gram-negative and gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis. 2005;52:215-27.
18. Wallace RJ Jr, Brown-Elliott BA, Crist CJ, Mann L, Wilson RW. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob Agents Chemother. 2002;46:3164-7.
19. Goldstein EJC, Citron DM, Merriam CV, Warren Y, Tyrrell K. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother. 2000;44:2747-51
20. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis. 2004;49:201-9.
21. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis. 2005;52:181-6.
22. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother. 2006;57:573-6.
23. Bradford PA, Petersen PJ, Young M, Jones CH, Tischler M, O'Connell J. Tigecycline MIC testing by broth dilution requires use of fresh medium or addition of the biocatalytic oxygen-reducing reagent oxyrase to standardize the test method. Antimicrob Agents Chemother. 2005;49:3903-9.
24. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Microbiol Infect. 2006;43:518-24
25. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58:1221-9.
26. EUCAST technical note on tygecycline. Clin Microbiol Infect. 2006;12:1147-9.
27. Silverman JA, Perlmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:2538-44.
28. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the daptomycin surveillance programme (2002-2004). Clin Microbiol Infect. 2006;12:844-52.
29. Streit JM, Jones RN, Sader HS. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical gram-positive organisms. J Antimicrob Chemother. 2004;53:669-74
30. Wiedemann B. Test results: characterising the antimicrobial activity of daptomycin. Clin Microbiol Infect. 2006;12 Suppl 8:9-14.
31. Cui L, Tominaga E, Neoh H, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:1079-82
32. Jorgensen JH, Crawford SA, Kelly CC, Patterson JE. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother. 2003;47:3760-3.
33. Fuchs PC, Barry AL, Brown SD. Evaluation of daptomycin susceptibility testing by Etest and the effect of different batches of media. J Antimicrob Chemother. 2001;48:557-61.
34. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother. 2003;47:1318-23.
35. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother. 2006;50:3245-9.
36. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother. 2002;46:31-3.
37. Ammerlaan HSM, Bonten MJM. Daptomycin: graduation day. Clin Microbiol Infect. 2006;12 Suppl 8:22-8.
38. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991;35:2505-8.
39. Garrison MW, Vance-Bryan K, Larson TA, Toscano JP, Rotschafer JC. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1990;34:1925-31.
40. Silverman JA, Mortin LI, VanPraagh ADG, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149-52.
41. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63-8.
42. EUCAST technical note on daptomycin. Clin Microbiol Infect. 2006;12:599-601.
43. Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem Pharmacol. 2006;71:968-80.
44. Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother. 2007;51:1150-4.
45. Streit JM, Fritsche TR, Sader HS, Jones RN. Worldwide assessment of dalbavancin activity and spectrum against over 6 000 clinical isolates. Diagn Microbiol Infect Dis. 2004;48:137-43.
46. Lopez S, Hackbarth C, Romanò G, Trias J, Jabes D, Goldstein BP. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 2005;55 Suppl 2:21-4.
47. Streit JM, Sader HS, Fritsche T, Jones RN. Dalbavancin activity against selected populations of antimicrobial-resistant gram-positive pathogens. Diagn Microbiol Infect Dis. 2005;53:307-10.
48. Goldstein EJ, Citron DM, Meriam CV, Warren YA, Tyrrell KL, Fernández HT. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother. 2004;48:2149-52.
49. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother. 2004;53:797-803.
50. Pace JL, Krause K, Johnston D, Debabov D, Wu T, Farrington L, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:3602-4.
51. Barcia-Macay M, Lemaire S, Minueto-Leclerq M-P, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2006;58:1177-84.
52. Dorr MB, Jabes D, Cavaleri M, Dowell J, Mosconi G, Malabarba A, et al. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide. J Antimicrob Chemother. 2005; 55 Suppl 2:25-30.
53. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37:1298-303.
54. Andes D, Craig WA. In vivo pharmacodynamic activity of the glycopeptide, dalbavancin. Antimicrob Agents Chemother. 2007;51:1633-42.
55. Stryjewski ME, Chu VH, O'Riordan WD, Warrenn BL, Dunbar LM, Young DM, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50:862-7.
56. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40:1601-7.
57. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005;49:195-201.
58. Sun HK, Duchin K, Nightingale CH, Shaw J-P, Seroogy J, Nicolau P. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother. 2006;50:788-90.
59. Hegde SS, Reyes N, Wiens T, Vanasse N, Skinner R, McCullough J, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria. Antimicrob Agents Chemother. 2004;48:3043-50.
60. Mouton JW, Schmitt-Hoffmann A, Shapiro S, Nashed N, Punt NC. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob Agents Chemother. 2004;48:1713-8.
61. Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 2005;49:4210-9.
62. Jones RN, Deshpande LM, Mutnick AH, Biedenbach DJ. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J Antimicrob Chemother. 2002;50:915-32.
63. Hebeisen P, Heinze-Krauss I, Angehrn P, Hohl P, Page MGP, Then RL. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother. 2001;45:825-36.
64. Schmitt-Hoffmann A, Nyman L, Roos B, Schleimer M, Sauer J, Nashed N, et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004;48:2576-80
65. Soriano F, Fernández-Roblas R, Calvo R, García-Calvo G. In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials. Antimicrob Agents Chemother 1998;42:1028-33.